Abstract: The disclosure relates to dosage forms which include one or more cohesion agents in amounts effective to reduce the likelihood and ease of extraction of an opioid agonist therefrom. The dosage forms exhibit improved resistance to abuse and lesser likelihood of accidental overdosing than similar dosage forms lacking a cohesion agent. Dosage forms including a lipid or waxy component, a cellulose-based release inhibitor, a thixotrope, one or more cohesion agents, and at least one sequestered opioid antagonist. The dosage forms capable of inhibiting or reducing extraction, abuse, or overdose involving the opioid agonist over a broad range of temperatures are disclosed. The dosage forms also deter extraction of the opioid therefrom.

Abstract: The disclosure relates to dosage forms which include one or more cohesion agents in amounts effective to reduce the likelihood and ease of extraction of an opioid agonist therefrom. The dosage forms exhibit improved resistance to abuse and lesser likelihood of accidental overdosing than similar dosage forms lacking a cohesion agent. Dosage forms including multiple cohesion agents capable of inhibiting or reducing extraction, abuse, or overdose over a broad range of temperatures are disclosed.

Abstract: A process for preparing solid, amorphous paroxetine comprising: (A) mixing paroxetine free base or a pharmaceutically acceptable paroxetine salt with water and pharmaceutically acceptable polymer; and (B) drying to form a composition comprising amorphous paroxetine and polymer, eliminating the need for organic solvents common for the solvent process. The resultant amorphous solid paroxetine composition is free from crystalline form, and yet has good handling properties, making it suitable for pharmaceutical use in the traditional tablet dosage form.